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EDITORIAL
Congenital myasthenic syndromes and 
myasthenia gravis are challenging diagnoses 
in neurological practice
Síndromes miastênicas congênitas e miastenia Grave são diagnósticos desafiadores na 
prática neurológica
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Myasthenia is abnormal fatigability on exertion that is present in a variety of syndromes and diseases with different pathogenesis due to autoantibodies, toxins, drugs and genetic defects. They all have in common a deficient cou-pling of excitation-contraction in the neuromuscular junction (NMJ), either 
in its presynaptic, synaptic or postsynaptic regions1.
Acquired autoimmune myasthenia gravis (MG) is the most prevalent myasthenia type, and 
is a postsynaptic NMJ’s disorder, with heterogeneous clinical and antibodies presentation2. 
Antibody against the nicotinic acetylcholine receptor (AChR) was the first discovered and it is 
present in about 85% of generalized MG or in 50% in ocular MG, which is AChR-MG2. AChR-MG 
shows decremental compound muscle action potential (CMAP) on repetitive nerve stimula-
tion at 2-3 Hz and when this exam is negative, the single-fiber electromyography increases the 
chances of diagnose1. Distinction between thymomatous- and nonthymomatous-MG, espe-
cially in the elderly with late onset MG, is absolutely necessary, since the first one is managed 
with oncologic therapy as well. Nonthymomatous-MG can be treated with acetylcholinester-
ase inhibitors, immunosuppressive drugs 2 and thymectomy 3.
In 40% of seronegative-AChR-MG (SNMG), using standard radioimmunoassay, the serum 
antibody directed to the muscle-specific tyrosine kinase (MuSK) is positive, characterizing the 
subgroup of MuSK-MG2. The clinical characteristics of MuSK-MG are facial, bulbar and neck 
fatigable weakness, partial response to acetylcholinesterase inhibitors, response to rituximab 
in some patients and, no abnormalities in thymus2. 
Recently, a third autoantibody was found in 4 to 45% of double-SNMG cases, this large range 
of variation is due to the methods employed2,4. The low-density lipoprotein receptor-related 
protein 4 (Lrp4), a receptor for agrin, is the target of this antibody. Authors4 found 14.3% of 
positive Lrp4 antibody in an Italian series of 55 double-SNMG patients and clinical correlation 
for Lrp4-MG is thus emerging: female patients with mild or moderate myasthenia, according 
to Myasthenia Gravis Foundation of America scores, and without specific thymus abnormali-
ties4. However, to draw more definitive conclusions, further efforts are needed in collecting 
more data through larger series.
Lambert-Eaton myasthenic syndrome (LEMS) and botulism are presynaptic NMJ’s dys-
function with autoimmune and toxic pathogenesis, respectively1. In LEMS an antibody against 
P/Q type voltage-gated calcium channel is positive in patients with small-cell lung cancer 
and other tumors or in patient without any neoplasia (even after a long lasting follow-up). 
Fatigability is predominant in limb girdle, frequently associated with hyporreflexia and auto-
nomic dysfunctions2. Repetitive nerve stimulation is characteristic1.
Congenital myasthenic syndromes (CMS) are rarer than MG and their onset occurs at 
birth, shortly after it or in early childhood. Their pathogenesis is related to genetic defects 
affecting structural and functional NMJ’s proteins, inherited more frequently as autosomal 
recessive trace5. CMS diagnosis is based on detailed clinical findings and confirmed upon de-
tection of the CMAP decrement on 2-3 Hz nerve stimulation1 (eventually double CMAP in 
single stimulus, disappearing after brief voluntary contraction6) or increased/blocking jitter 
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on single-fiber electromyography1. Other two criteria must 
be considered, absence of serum antibodies and no improve-
ment with immunosuppressive therapy1. Thus, detailed clin-
ical and neurophysiological exams raise the hypothesis of 
CMS. Next generation sequencing of genes may confirm the 
already known CMS subtypes or whole-exome sequencing 
may suspect a new causative gene7. 
In 2009 a Brazilian case-report of end-plate acetylcholin-
esterase deficiency with proven genetic mutation was pub-
lished6, and a year later, a CMS series of cases came from the 
Southern region8. The authors estimated a minimum preva-
lence of 0.18 cases per 100.000 in the State of Parana and the 
most frequent mutation was in CHRNE gene, which is respon-
sible for coding the εAChR subunit. The second mutation in 
frequency was documented in DOK7 gene8. Interestingly, the 
same mutation was observed in Spain and Portugal, nations 
with significant role in the immigration process of the men-
tioned area. Since our large country has regions of different 
ethnic background, it will be of practical importance to uncov-
er the genetic epidemiology of CMS in other regions of Brazil. 
In this issue of Arquivos de Neuropsiquiatria, Souza et al.9 
present a comprehensive review on CMS that will be of great 
interest to the readers, as they included clinic, genetic and 
therapeutic particularities according to CMS subtypes.
CMS mostly manifest in the first two years of life, lead-
ing to difficulties in the differential diagnose with con-
genital myopathies. Not to mention that same congeni-
tal myopathies may still be associated with myasthenic 
symptoms 10. Another great challenge is differentiate be-
tween CMS and early onset AChR-MG or with MusK-MG, 
when they are seronegative.
Considering the importance of genetic testing in the final 
diagnose of CMS8,9 and that it is costly and only available in 
few centers of Brazil, it seems to be of a high demand to re-
verse this situation. Early and definite diagnoses in CMS lead 
to a better rational therapeutic choice in benefit to patients.
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